Buruli Ulcer

A lesion in the skin and subcutaneous tissues due to infections by MYCOBACTERIUM ULCERANS. It was first reported in Uganda, Africa.

Also Known As:

Buruli Ulcer Disease; Infections, Mycobacterium ulcerans; Buruli Ulcer Diseases; Disease, Buruli Ulcer; Diseases, Buruli Ulcer; Infection, Mycobacterium ulcerans; Mycobacterium ulcerans Infections; Ulcer Disease, Buruli; Ulcer Diseases, Buruli; Ulcer, Buruli; Mycobacterium ulcerans Infection

Networked: 335 relevant articles (26 outcomes, 27 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Buruli Ulcer
2.	Infections
3.	Coinfection
4.	Cicatrix (Scar)
5.	Thrombosis (Thrombus)

Experts

1.	Pluschke, Gerd: 40 articles (01/2022 - 01/2006)
2.	Portaels, Françoise: 21 articles (01/2018 - 03/2002)
3.	Demangel, Caroline: 18 articles (01/2022 - 08/2005)
4.	Ruf, Marie-Thérèse: 17 articles (01/2022 - 08/2011)
5.	Converse, Paul J: 16 articles (01/2022 - 01/2011)
6.	Nuermberger, Eric L: 16 articles (01/2022 - 07/2010)
7.	Marsollier, Laurent: 16 articles (12/2021 - 04/2003)
8.	Phillips, Richard O: 15 articles (04/2020 - 05/2009)
9.	Stienstra, Ymkje: 15 articles (04/2020 - 06/2003)
10.	Johnson, Paul D R: 15 articles (01/2020 - 10/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Buruli Ulcer:

1.	Rifampin (Rifampicin)FDA LinkGeneric 04/01/2014 - "Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease." 04/01/2003 - "By use of a murine model for Buruli ulcer, Mycobacterium ulcerans was found to be susceptible to rifampin, with the MIC being 0.5 to 1 micro g/ml. Three mutants were isolated after rifampin monotherapy. " 02/01/1972 - "Rifampicin in experimental Mycobacterium ulcerans infection." 09/01/1979 - "Mycobacterium ulcerans infection: treatment with rifampin, hyperbaric oxygenation, and heat." 10/01/2002 - "To identify the most active curative treatment of Buruli ulcer, two regimens incorporating the use of rifampin (RIF) were compared with the use of RIF alone in a mouse footpad model of Mycobacterium ulcerans infection. "
2.	Anti-Bacterial Agents (Antibiotics)IBA 10/01/2019 - "Antibiotic treatment proved itself as the mainstay of treatment for Buruli ulcer disease. " 01/01/2020 - "Buruli ulcer: cured by 8 weeks of oral antibiotics?" 11/01/2016 - "This study evaluated contaminating bacterial flora and their antibiotic susceptibility patterns in cases of previously untreated Buruli ulcer disease from three states in Southern Nigeria. " 07/01/2014 - "To study the Quality of Life (QoL) of former Buruli Ulcer patients who, in the context of a randomized controlled trial, reported early with small lesions (cross-sectional diameter <10 cm), and received a full course of antibiotic treatment. " 01/01/2021 - "Current treatments for Buruli ulcer are efficacious, but rely on the use of antibiotics with severe side effects. "
3.	Streptomycin (Streptomycin Sulfate)FDA Link 03/01/2014 - "Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial." 07/01/2007 - "[Streptomycin injections for the treatment of Mycobacterium ulcerans (Buruli ulcer) in a rural health zone in the Democratic Republic of the Congo]." 07/01/2017 - "Buruli ulcer (BU) caused by Mycobacterium ulcerans is effectively treated with rifampicin and streptomycin for 8 weeks but some lesions take several months to heal. " 08/01/2005 - "Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans." 01/04/2011 - "treatment of Mycobacterium ulcerans disease, or Buruli ulcer (BU), has shifted from surgery to treatment with streptomycin(STR)+rifampin(RIF) since 2004 based on studies in a mouse model and clinical trials. "
4.	VaccinesIBA 12/08/2021 - "This study systematically reviews the literature to identify and describe candidate prophylactic Buruli ulcer vaccines. " 04/01/2022 - "The search for a Buruli Ulcer vaccine and the effectiveness of the Bacillus Calmette-Guérin vaccine." 12/08/2021 - "Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis." 01/01/2020 - "Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model." 05/05/2015 - "Our observations should facilitate development of effective vaccines against Buruli ulcer for control of this disease. "
5.	Clarithromycin (Biaxin)FDA LinkGeneric 01/01/2020 - "We aimed to compare the efficacy and tolerability of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8) with that of RS8 for treatment of early Buruli ulcer lesions. " 09/01/2010 - "Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection." 11/03/2008 - "Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin." 01/01/2021 - "Clarithromycin and amikacin are likely suitable drugs for clearance of secondary infection of Buruli ulcer." 01/01/2020 - "Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial."
6.	ClayIBA 01/30/2016 - "ulcerans and assessed the in vivo efficacy of topically-applied, hydrated clays on Buruli ulcer progression in mice infected with M. " 01/30/2016 - "ulcerans and that hydrated clay poultices may offer a complementary and integrative strategy for topically treating Buruli ulcer disease." 08/01/2008 - "This paper compares the mineralogy and chemical composition of the two French green clays used in the treatment of Buruli ulcer.Mineralogically" 01/30/2016 - "For animal experiments, we examined the effect of topical hydrated clay therapy on Buruli ulcer progression in vivo in mouse tails subcutaneously infected with M. " 08/01/2008 - "Assessing the antibacterial properties of these clays could provide an inexpensive treatment for Buruli ulcer and other skin infections.Antimicrobial"
7.	AntigensIBA 01/01/2018 - "The major response to PKS antigen stimulation was IFN-γ and the strongest responses were observed in healthy contacts of patients living in areas endemic for Buruli ulcer. " 03/01/2000 - "Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease." 10/01/1976 - "Lymphocyte-transformation responses to mycobacterial antigens have been studied, using paired blood and lymph node samples from 'normal' Ugandans, (hernia repairs or orthopaedic cases) or from patients with tuberculosis, Mycobacterium ulcerans infection, or injection abscesses. " 01/01/2020 - "High antibody titres induced by protein subunit vaccines using Mycobacterium ulcerans antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice." 01/01/2018 - "More than 80% of patients and contacts from endemic areas produced IFN-γ in response to all the antigens except acyl carrier protein type 3 (ACP3) to which only 47% of active Buruli ulcer cases and 71% of contacts responded. "
8.	AntibodiesIBA 12/01/2006 - "Anti-18-kDa shsp antibodies were frequently found in the sera of Buruli ulcer patients and of healthy household contacts but rarely found in controls from regions where the infection is not endemic. " 02/01/2016 - "Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer." 01/01/2019 - "In the past, it has proved challenging to generate antibodies against mycolactone, the primary lipidic toxin A of Mycobacterium ulcerans causing Buruli ulcer, due to its immunosuppressive properties. " 01/01/2020 - "We demonstrate the production of skin-specific antibodies neutralizing the immunomodulatory activity of the mycolactone toxin, and confirm the role of human host machinery in triggering effective local immune responses by the detection of anti-mycolactone antibodies in patients with Buruli ulcer. " 01/01/2014 - "However, antibodies against some of the polyketide synthase domains involved in mycolactone synthesis, were found in Buruli ulcer patients and healthy controls from the same endemic region, suggesting that these domains are indeed immunogenic. "
9.	BCG Vaccine FDA Link 01/01/2021 - "Bacillus Calmette-Guérin (BCG) vaccine provides partial protection against Buruli ulcer caused by Mycobacterium ulcerans in epidemiological studies. " 01/01/2015 - "Even though the BCG vaccine is still widely used, results on its effectiveness in preventing mycobacterial diseases are partially contradictory, especially regarding Buruli Ulcer Disease (BUD). " 10/01/2006 - "BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin."
10.	telacebecIBA 10/18/2021 - "Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer." 10/18/2021 - "Telacebec (Q203) is a new antituberculosis drug in clinical development that has extremely potent activity against Mycobacterium ulcerans, the causative agent of Buruli ulcer (BU). " 01/01/2020 - "Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease." 01/01/2020 - "Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model." 01/01/2020 - "A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. "

Therapies and Procedures

1.	Therapeutics 11/04/2010 - "The data provide a basis for the understanding of Buruli ulcer pathology and the development of improved therapies for this disease." 01/01/2020 - "Therefore, we propose that fully oral RC8 should be the preferred therapy for early, limited lesions of Buruli ulcer. " 01/01/2019 - "Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay." 01/01/2018 - "An understudied disease, little research thus far has explored responses to Buruli ulcer and quests for therapy from biosocial perspective, despite reports that people seek biomedical treatment too late. " 01/01/2016 - "Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy."
2.	Combination Drug Therapy (Combination Chemotherapy) 04/01/2014 - "While traditionally surgery has dominated the clinical management of Buruli ulcer (BU), the introduction of the combination chemotherapy with oral rifampicin and intramuscular streptomycin greatly improved treatment and reduced recurrence rates. " 02/01/2012 - "Combination chemotherapy with rifampin and streptomycin (RIF-STR) for 8 weeks is currently recommended by the WHO as the first-line treatment for Mycobacterium ulcerans infection (Buruli ulcer). "
3.	Drug Therapy (Chemotherapy) 01/01/2012 - "Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy--a case report from Togo." 11/01/2022 - "Biological confirmation of clinical diagnosis of Buruli ulcer is essential before starting chemotherapy. " 02/01/2012 - "Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model." 09/01/2011 - "Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue?" 08/01/2011 - "Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?"
4.	Secondary Prevention 10/01/2007 - "In spite of possible defects in the methodology of a before/after survey the incidence decrease of both ulcerative and nodular forms that coincided with the prevention program probably reflects the efficacy of the secondary prevention program that promotes early diagnosis and treatment of nodular forms of Mycobacterium ulcerans infection." 10/01/2007 - "[Impact of Buruli ulcer secondary prevention program in an endemic area in Côte d'Ivoire]."
5.	Occlusive Dressings (Occlusive Dressing) 01/01/2018 - "We present here a case of Buruli ulcer treated successfully with a preoperative mapping biopsy procedure, which had been self-medicated with occlusive dressing. " 01/01/2018 - "Mapping biopsy for Buruli ulcer self-medicated with occlusive dressing." 01/01/2018 - "Because Buruli ulcer is accompanied by subtle pain, patients and clinicians tend to initially treat the ulcer with occlusive dressing therapy, which leads to the misdiagnosis of Buruli ulcer as a common bacterial infection only judging from bacterial culture of the surface of the ulcer. "